Greenleaf Trust raised its holdings in shares of GSK plc (NYSE:GSK – Get Rating) by 17.8% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 11,124 shares of the pharmaceutical company’s stock after purchasing an additional 1,682 shares during the quarter. Greenleaf Trust’s holdings in GSK were worth $391,000 at the end of the most recent quarter.
A number of other hedge funds have also recently bought and sold shares of the business. Bard Financial Services Inc. acquired a new stake in GSK during the 4th quarter valued at approximately $219,000. Whittier Trust Co. grew its position in shares of GSK by 25.4% in the 4th quarter. Whittier Trust Co. now owns 44,170 shares of the pharmaceutical company’s stock worth $1,552,000 after acquiring an additional 8,944 shares in the last quarter. Thrive Wealth Management LLC grew its position in shares of GSK by 3.3% in the 4th quarter. Thrive Wealth Management LLC now owns 10,630 shares of the pharmaceutical company’s stock worth $374,000 after acquiring an additional 336 shares in the last quarter. Lindbrook Capital LLC grew its position in shares of GSK by 20.5% in the 4th quarter. Lindbrook Capital LLC now owns 2,565 shares of the pharmaceutical company’s stock worth $90,000 after acquiring an additional 436 shares in the last quarter. Finally, Kooman & Associates acquired a new position in shares of GSK in the 4th quarter worth approximately $200,000. Institutional investors and hedge funds own 13.15% of the company’s stock.
GSK Stock Up 1.5 %
Shares of GSK stock opened at $38.00 on Friday. The business’s fifty day moving average price is $35.18 and its two-hundred day moving average price is $33.99. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.91 and a quick ratio of 0.68. The company has a market capitalization of $81.92 billion, a P/E ratio of 4.43, a PEG ratio of 1.83 and a beta of 0.67. GSK plc has a 1-year low of $28.47 and a 1-year high of $46.97.
GSK Cuts Dividend
The firm also recently announced a quarterly dividend, which will be paid on Thursday, April 13th. Shareholders of record on Friday, February 24th will be paid a dividend of $0.3404 per share. This represents a $1.36 annualized dividend and a yield of 3.58%. The ex-dividend date is Thursday, February 23rd. GSK’s payout ratio is currently 15.50%.
Wall Street Analyst Weigh In
GSK has been the subject of several research reports. JPMorgan Chase & Co. lifted their target price on GSK from GBX 1,350 ($16.77) to GBX 1,400 ($17.39) in a research report on Thursday, February 2nd. TheStreet upgraded GSK from a “c+” rating to a “b-” rating in a research report on Friday, December 30th. The Goldman Sachs Group initiated coverage on GSK in a research report on Sunday, February 26th. They set a “buy” rating for the company. Berenberg Bank boosted their price objective on GSK from GBX 1,580 ($19.62) to GBX 1,730 ($21.49) in a research report on Friday, February 10th. Finally, Deutsche Bank Aktiengesellschaft upgraded GSK from a “hold” rating to a “buy” rating in a research report on Friday, March 17th. Three research analysts have rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $1,576.88.
GSK Company Profile
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Commercial Operations, Research and Development, and Consumer Healthcare. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Featured Stories
- Get a free copy of the StockNews.com research report on GSK (GSK)
- Costco Sales Disappoint, Markets Are Missing This Upside Driver
- First Republic Bank Is A Speculative Play, Here’s Why
- The WD-40 Company Bottoms With Reversal In Sight
- 3 Low-Cost Stock ETFs That Are Crushing It This Year
- FedEx Takes Flight; Analysts See More Gains Ahead
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.
